BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22512864)

  • 1. Cyclin K goes with Cdk12 and Cdk13.
    Kohoutek J; Blazek D
    Cell Div; 2012 Apr; 7():12. PubMed ID: 22512864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing.
    Liang K; Gao X; Gilmore JM; Florens L; Washburn MP; Smith E; Shilatifard A
    Mol Cell Biol; 2015 Mar; 35(6):928-38. PubMed ID: 25561469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
    Greenleaf AL
    Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and Functional Analysis of the Cdk13/Cyclin K Complex.
    Greifenberg AK; Hönig D; Pilarova K; Düster R; Bartholomeeusen K; Bösken CA; Anand K; Blazek D; Geyer M
    Cell Rep; 2016 Jan; 14(2):320-31. PubMed ID: 26748711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
    Choi SH; Kim S; Jones KA
    Exp Mol Med; 2020 May; 52(5):762-771. PubMed ID: 32451425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
    Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
    Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation.
    Schmitz M; Kaltheuner IH; Anand K; Düster R; Moecking J; Monastyrskyi A; Duckett DR; Roush WR; Geyer M
    J Biol Chem; 2024 Jan; 300(1):105501. PubMed ID: 38016516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.
    Fan Z; Devlin JR; Hogg SJ; Doyle MA; Harrison PF; Todorovski I; Cluse LA; Knight DA; Sandow JJ; Gregory G; Fox A; Beilharz TH; Kwiatkowski N; Scott NE; Vidakovic AT; Kelly GP; Svejstrup JQ; Geyer M; Gray NS; Vervoort SJ; Johnstone RW
    Sci Adv; 2020 May; 6(18):. PubMed ID: 32917631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression.
    Chen HR; Lin GT; Huang CK; Fann MJ
    Exp Neurol; 2014 Nov; 261():10-21. PubMed ID: 24999027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
    Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
    Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II.
    Cheng SW; Kuzyk MA; Moradian A; Ichu TA; Chang VC; Tien JF; Vollett SE; Griffith M; Marra MA; Morin GB
    Mol Cell Biol; 2012 Nov; 32(22):4691-704. PubMed ID: 22988298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role and therapeutic potential of CDK12 in human cancers.
    Chilà R; Guffanti F; Damia G
    Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1.
    Bartkowiak B; Liu P; Phatnani HP; Fuda NJ; Cooper JJ; Price DH; Adelman K; Lis JT; Greenleaf AL
    Genes Dev; 2010 Oct; 24(20):2303-16. PubMed ID: 20952539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
    Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
    Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing.
    Chen HH; Wong YH; Geneviere AM; Fann MJ
    Biochem Biophys Res Commun; 2007 Mar; 354(3):735-40. PubMed ID: 17261272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.
    Chen HH; Wang YC; Fann MJ
    Mol Cell Biol; 2006 Apr; 26(7):2736-45. PubMed ID: 16537916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma.
    Houles T; Boucher J; Lavoie G; MacLeod G; Lin S; Angers S; Roux PP
    Cell Death Discov; 2023 Dec; 9(1):459. PubMed ID: 38104154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, purification, and identification of associated proteins of the full-length hCDK12/CyclinK complex.
    Bartkowiak B; Greenleaf AL
    J Biol Chem; 2015 Jan; 290(3):1786-95. PubMed ID: 25429106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDK12: an emerging therapeutic target for cancer.
    Lui GYL; Grandori C; Kemp CJ
    J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK12: cellular functions and therapeutic potential of versatile player in cancer.
    Pilarova K; Herudek J; Blazek D
    NAR Cancer; 2020 Mar; 2(1):zcaa003. PubMed ID: 34316683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.